Beigene Ltd (NASDAQ:BGNE) shares saw unusually-strong trading volume on Monday . Approximately 115,077 shares were traded during trading, an increase of 117% from the previous session’s volume of 53,141 shares.The stock last traded at $24.73 and had previously closed at $26.24.

Several research analysts have commented on BGNE shares. Morgan Stanley boosted their target price on Beigene from $39.00 to $42.00 in a research note on Friday, April 8th. Cowen and Company reissued a “buy” rating on shares of Beigene in a research note on Thursday, May 12th. Finally, Zacks Investment Research downgraded Beigene from a “hold” rating to a “sell” rating in a research note on Monday, May 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $39.67.

The stock’s market capitalization is $586.48 million. The stock’s 50-day moving average is $29.05 and its 200-day moving average is $28.85.

Beigene (NASDAQ:BGNE) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.92. The company earned $0.70 million during the quarter. The firm’s revenue was down 50.0% compared to the same quarter last year. On average, analysts expect that Beigene Ltd will post ($3.17) EPS for the current fiscal year.

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.